Inner City Gazette

Page 1

y

e

Fre

Full &

p Co

everyday

lessons running

Grade R -11 Metropolitan College 170 Pritchard Street Tel – 011 402 9502

Est 2009 Issue 04 - 2021

Tel : 011 616 1523

Email : info@inner-city-gazette.co.za

Inner-City Gazette

@ICG_Sales

28 January - 4 February 2021

Website : www.inner-city-gazette.co.za 072 824 3014

Inner City Gazette

Producers to supply vaccines to Covax

The WHO, the Coalition for Epidemic Preparedness Innovations (CEPI), and GAVI, the Vaccine Alliance, launched Covax in April to prevent wealthier countries from hoarding vital doses of the vaccine. Grace Dean

P

World Health Organisation director Dr Tedros Ghebreyesus

harmaceutical companies Pfizer and BioNTech will supply a quantity of their Covid-19 vaccine to Covax, which was set up by health organisations that include the World Health Organisation (WHO) to provide equal distribution of vaccines worldwide. Two sources with knowledge of the matter told Reuters that Pfizer and BioNTech will supply Covid-19 vaccines to Covax, the World Health Organisation (WHO) scheme designed to share doses with poorer countries, South Africa expects to get vaccines for 10% of its population via Covax, for a payment of R2.2 billion. The number of doses Pfizer and BioNTech share with the scheme would likely be relatively small, sources said. One said the doses were mainly intended for healthcare workers. The news came a day after Dr Anthony Fauci, US President Joe Biden’s chief medical advisor, said the new administration plans to join Covax. Former president Donald Trump had cut ties with the WHO and refused to sign up to the scheme. The sources did not share information on how much Covax would pay for the doses. Pfizer and BioNTech did not immediately respond to requests for comment. The WHO, the Coalition for Epidemic

Preparedness Innovations (CEPI), and GAVI, the Vaccine Alliance, launched Covax in April to prevent wealthier countries from hoarding vital doses of the vaccine. Countries sign up to access an equal share of successful vaccine candidates, meaning that the doses are shared among richer and poorer countries. The scheme aims to provide lower-income countries with enough doses to cover 20% of their population. The groups behind the initiative described it as a lifeline, and the only viable way citizens in some of the poorest countries will get the vaccines. But the scheme has struggled to amass as many doses as expected, and even its founders are worried about the initiative. Many wealthy countries that signed up to the scheme, including the UK, EU, and Canada, have struck “side-deals” with pharmaceutical companies to guarantee their supply, researchers at Duke University found. Most of these deals were arranged prior to the vaccines’ approval, whereas Covax has been hesitant to order stocks before they are approved. In December, WHO vaccine director Dr Katherine O’Brien said: “The whole call for global solidarity has mostly been lost.” WHO director-general Dr Tedros Ghebreyesus said: “The world is on the brink of catastrophic moral failure by failing to give vaccines to poorer countries.”

On Thursday, Covax lowered its forecast from delivering more than 2 billion Covid-19 doses worldwide this year to around 1.8 billion. With this, it plans to vaccinate around 27% of the population of 92 poor countries, it said. Pfizer-BioNTech’s shot, if confirmed, would become the second vaccine supplied to the scheme that already has regulatory approval in some countries, alongside the AstraZeneca-Oxford University shot. Covax also has deals with the Serum Institute of India and Sanofi-GSK, but their shots are still in trial stages. Pfizer-BioNTech’s vaccine could be tricky to roll out in the countries that Covax was designed to help. It has to be transported at 94 degrees Fahrenheit, causing potential problems with distribution and storage, even in wealthy countries. Global health policy Professor Ted Schrecker at Newcastle University Medical School said as well as lacking the right transport infrastructure, rural settlements in low-income countries may not even have access to a working fridge. In comparison, AstraZeneca-Oxford’s Covid-19 vaccine, which is among those with deals with Covax, can be stored, transported, and handled at normal fridge temperatures for at least six months and “administered within existing healthcare settings.” Business Insider


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.